TIZITA TESSEMA: Open Payments
NPI 1528612397 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$495 in 23 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $192 · 2025 $495
Food & beverage: $495
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $102 |
| PFIZER INC. | 4 | $78 |
| Amgen Inc. | 4 | $75 |
| AstraZeneca Pharmaceuticals LP | 3 | $73 |
| Novo Nordisk Inc | 2 | $44 |
| Merck Sharp & Dohme LLC | 2 | $43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| ABBVIE INC. | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $19 |
Products named: MOUNJARO, ELIQUIS, AIRSUPRA, OTEZLA, GARDASIL 9, JARDIANCE, REPATHA, QULIPTA.
Industry payments across DC — which companies pay providers there.
